collection
https://read.qxmd.com/read/32518675/nonalcoholic-fatty-liver-disease-and-type-2-diabetes-where-do-diabetologists-stand
#1
REVIEW
Shaheen Tomah, Naim Alkhouri, Osama Hamdy
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. The increasing prevalence of NAFLD mirrors that of obesity and type 2 diabetes over the last two decades. MAIN: In a two-way pathophysiologic relationship, NAFLD increases the risk of developing type 2 diabetes, while the latter promotes the progression of simple fatty liver to a more advanced form called nonalcoholic steatohepatitis (NASH). NASH increases the risk of cirrhosis and hepatocellular carcinoma (HCC), which may require liver transplantation...
2020: Clinical Diabetes and Endocrinology
https://read.qxmd.com/read/32561617/precision-medicine-in-diabetes-a-consensus-report-from-the-american-diabetes-association-ada-and-the-european-association-for-the-study-of-diabetes-easd
#2
REVIEW
Wendy K Chung, Karel Erion, Jose C Florez, Andrew T Hattersley, Marie-France Hivert, Christine G Lee, Mark I McCarthy, John J Nolan, Jill M Norris, Ewan R Pearson, Louis Philipson, Allison T McElvaine, William T Cefalu, Stephen S Rich, Paul W Franks
The convergence of advances in medical science, human biology, data science, and technology has enabled the generation of new insights into the phenotype known as "diabetes." Increased knowledge of this condition has emerged from populations around the world, illuminating the differences in how diabetes presents, its variable prevalence, and how best practice in treatment varies between populations. In parallel, focus has been placed on the development of tools for the application of precision medicine to numerous conditions...
July 2020: Diabetes Care
https://read.qxmd.com/read/29508275/eadsg-guidelines-insulin-therapy-in-diabetes
#3
JOURNAL ARTICLE
Bahendeka Silver, Kaushik Ramaiya, Swai Babu Andrew, Otieno Fredrick, Sarita Bajaj, Sanjay Kalra, Bavuma M Charlotte, Karigire Claudine, Anthony Makhoba
A diagnosis of diabetes or hyperglycemia should be confirmed prior to ordering, dispensing, or administering insulin (A). Insulin is the primary treatment in all patients with type 1 diabetes mellitus (T1DM) (A). Typically, patients with T1DM will require initiation with multiple daily injections at the time of diagnosis. This is usually short-acting insulin or rapid-acting insulin analogue given 0 to 15 min before meals together with one or more daily separate injections of intermediate or long-acting insulin...
April 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://read.qxmd.com/read/28199805/bariatric-surgery-versus-intensive-medical-therapy-for-diabetes-5-year-outcomes
#4
RANDOMIZED CONTROLLED TRIAL
Philip R Schauer, Deepak L Bhatt, John P Kirwan, Kathy Wolski, Ali Aminian, Stacy A Brethauer, Sankar D Navaneethan, Rishi P Singh, Claire E Pothier, Steven E Nissen, Sangeeta R Kashyap
BACKGROUND: Long-term results from randomized, controlled trials that compare medical therapy with surgical therapy in patients with type 2 diabetes are limited. METHODS: We assessed outcomes 5 years after 150 patients who had type 2 diabetes and a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 27 to 43 were randomly assigned to receive intensive medical therapy alone or intensive medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy...
February 16, 2017: New England Journal of Medicine
https://read.qxmd.com/read/28325798/management-of-inpatient-hyperglycemia-and-diabetes-in-older-adults
#5
REVIEW
Guillermo E Umpierrez, Francisco J Pasquel
Adults aged 65 years and older are the fastest growing segment of the U.S. population, and their number is expected to double to 89 million between 2010 and 2050. The prevalence of diabetes in hospitalized adults aged 65-75 years and over 80 years of age has been estimated to be 20% and 40%, respectively. Similar to general populations, the presence of hyperglycemia and diabetes in elderly patients is associated with increased risk of hospital complications, longer length of stay, and increased mortality compared with subjects with normoglycemia...
April 2017: Diabetes Care
https://read.qxmd.com/read/28055075/oral-pharmacologic-treatment-of-type-2-diabetes-mellitus-a-clinical-practice-guideline-update-from-the-american-college-of-physicians
#6
JOURNAL ARTICLE
Amir Qaseem, Michael J Barry, Linda L Humphrey, Mary Ann Forciea, Nick Fitterman, Carrie Horwitch, Devan Kansagara, Robert M McLean, Timothy J Wilt
DESCRIPTION: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on oral pharmacologic treatment of type 2 diabetes in adults. This guideline serves as an update to the 2012 ACP guideline on the same topic. This guideline is endorsed by the American Academy of Family Physicians. METHODS: This guideline is based on a systematic review of randomized, controlled trials and observational studies published through December 2015 on the comparative effectiveness of oral medications for type 2 diabetes...
February 21, 2017: Annals of Internal Medicine
https://read.qxmd.com/read/28095040/consensus-statement-by-the-american-association-of-clinical-endocrinologists-and-american-college-of-endocrinology-on-the-comprehensive-type-2-diabetes-management-algorithm-2017-executive-summary
#7
JOURNAL ARTICLE
Alan J Garber, Martin J Abrahamson, Joshua I Barzilay, Lawrence Blonde, Zachary T Bloomgarden, Michael A Bush, Samuel Dagogo-Jack, Ralph A DeFronzo, Daniel Einhorn, Vivian A Fonseca, Jeffrey R Garber, W Timothy Garvey, George Grunberger, Yehuda Handelsman, Irl B Hirsch, Paul S Jellinger, Janet B McGill, Jeffrey I Mechanick, Paul D Rosenblit, Guillermo E Umpierrez
No abstract text is available yet for this article.
February 2017: Endocrine Practice
https://read.qxmd.com/read/27979887/standards-of-medical-care-in-diabetes-2017-summary-of-revisions
#8
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
January 2017: Diabetes Care
https://read.qxmd.com/read/27660695/update-on-the-treatment-of-type-2-diabetes-mellitus
#9
REVIEW
Juan José Marín-Peñalver, Iciar Martín-Timón, Cristina Sevillano-Collantes, Francisco Javier Del Cañizo-Gómez
To achieve good metabolic control in diabetes and keep long term, a combination of changes in lifestyle and pharmacological treatment is necessary. Achieving near-normal glycated hemoglobin significantly, decreases risk of macrovascular and microvascular complications. At present there are different treatments, both oral and injectable, available for the treatment of type 2 diabetes mellitus (T2DM). Treatment algorithms designed to reduce the development or progression of the complications of diabetes emphasizes the need for good glycaemic control...
September 15, 2016: World Journal of Diabetes
https://read.qxmd.com/read/25368673/colorectal-and-prostate-cancer-risk-in-diabetes-metformin-an-actor-behind-the-scene
#10
REVIEW
M Akhtar Anwar, Wassim Abou Kheir, Stephanie Eid, Joanna Fares, Xiaoqi Liu, Ali H Eid, Assaad A Eid
Both diabetes and cancer are prevalent diseases whose incidence rates are increasing worldwide, especially in countries that are undergoing rapid industrialization changes. Apparently, lifestyle risk factors including diet, physical inactivity and obesity play pivotal, yet preventable, roles in the etiology of both diseases. Epidemiological studies provide strong evidence that subjects with diabetes are at significantly higher risk of developing many forms of cancer and especially solid tumors. In addition to pancreatic and breast cancer, the incidence of colorectal cancer and prostate cancer is increased in type 2 diabetes...
2014: Journal of Cancer
https://read.qxmd.com/read/26322160/magnesium-and-type-2-diabetes
#11
REVIEW
Mario Barbagallo, Ligia J Dominguez
Type 2 diabetes is frequently associated with both extracellular and intracellular magnesium (Mg) deficits. A chronic latent Mg deficit or an overt clinical hypomagnesemia is common in patients with type 2 diabetes, especially in those with poorly controlled glycemic profiles. Insulin and glucose are important regulators of Mg metabolism. Intracellular Mg plays a key role in regulating insulin action, insulin-mediated-glucose-uptake and vascular tone. Reduced intracellular Mg concentrations result in a defective tyrosine-kinase activity, postreceptorial impairment in insulin action and worsening of insulin resistance in diabetic patients...
August 25, 2015: World Journal of Diabetes
https://read.qxmd.com/read/27214299/metformin-non-glycemic-effects-and-potential-novel-indications
#12
Abeer Anabtawi, John M Miles
Metformin is the most commonly prescribed drug for the treatment of type 2 diabetes because of its apparent robust effects in reducing cardiovascular risk. The United Kingdom Prospective Diabetes Study suggests that metformin reduces the risk of myocardial infarction, and more recent retrospective studies have shown an association between metformin and a reduction in stroke, atrial fibrillation and all-cause mortality. The mechanism(s) explaining these putative benefits are not clear but may involve decreased energy intake (with attendant weight loss), improvement in lipids, and lowering of blood pressure; a review of selected literature suggests that metformin lowers blood pressure when it is elevated, but not when it is normal...
May 23, 2016: Endocrine Practice
https://read.qxmd.com/read/27440829/sglt2-inhibitors-and-the-diabetic-kidney
#13
JOURNAL ARTICLE
Paola Fioretto, Alberto Zambon, Marco Rossato, Luca Busetto, Roberto Vettor
Diabetic nephropathy (DN) is the most common cause of end-stage renal disease worldwide. Blood glucose and blood pressure control reduce the risk of developing this complication; however, once DN is established, it is only possible to slow progression. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, the most recent glucose-lowering oral agents, may have the potential to exert nephroprotection not only through improving glycemic control but also through glucose-independent effects, such as blood pressure-lowering and direct renal effects...
August 2016: Diabetes Care
https://read.qxmd.com/read/26928912/diagnosis-and-management-of-diabetes-synopsis-of-the-2016-american-diabetes-association-standards-of-medical-care-in-diabetes
#14
JOURNAL ARTICLE
James J Chamberlain, Andrew S Rhinehart, Charles F Shaefer, Annie Neuman
DESCRIPTION: The American Diabetes Association (ADA) published the 2016 Standards of Medical Care in Diabetes (Standards) to provide clinicians, patients, researchers, payers, and other interested parties with the components of diabetes care, general treatment goals, and tools to evaluate the quality of care. METHODS: The ADA Professional Practice Committee performed a systematic search on MEDLINE to revise or clarify recommendations based on new evidence. The committee assigns the recommendations a rating of A, B, or C, depending on the quality of evidence...
April 19, 2016: Annals of Internal Medicine
https://read.qxmd.com/read/27273731/effect-of-adding-liraglutide-vs-placebo-to-a-high-dose-lnsulin-regimen-in-patients-with-type-2-diabetes-a-randomized-clinical-trial
#15
RANDOMIZED CONTROLLED TRIAL
Anna Vanderheiden, Lindsay Harrison, Jeremy Warshauer, Xilong Li, Beverley Adams-Huet, Ildiko Lingvay
IMPORTANCE: An increasing number of patients with type 2 diabetes are treated with high doses of insulin. Such treatment is associated with weight gain, hypoglycemia, and high treatment burden. OBJECTIVE: To assess the effectiveness and safety of adding a glucagon-like peptide 1 receptor agonist to the treatment regimen of patients with type 2 diabetes requiring therapy with high-dose insulin. DESIGN, SETTING, AND PARTICIPANTS: This clinical trial was a double-blind, placebo-controlled, randomized (1:1) study with 6 months of follow-up, conducted from August 13, 2012, to February 9, 2015, at ambulatory clinics at the University of Texas Southwestern Medical Center and Parkland Hospital...
July 1, 2016: JAMA Internal Medicine
https://read.qxmd.com/read/27076876/diabetic-foot-disease-from-the-evaluation-of-the-foot-at-risk-to-the-novel-diabetic-ulcer-treatment-modalities
#16
REVIEW
Noha Amin, John Doupis
The burden of diabetic foot disease (DFD) is expected to increase in the future. The incidence of DFD is still rising due to the high prevalence of DFD predisposing factors. DFD is multifactorial in nature; however most of the diabetic foot amputations are preceded by foot ulceration. Diabetic peripheral neuropathy (DPN) is a major risk factor for foot ulceration. DPN leads to loss of protective sensation resulting in continuous unconscious traumas. Patient education and detection of high risk foot are essential for the prevention of foot ulceration and amputation...
April 10, 2016: World Journal of Diabetes
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.